Feng Yong, Wei Wei, Guo Shuo, Li Bao-Qing
Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
Department of Outpatient, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
Oncol Lett. 2022 Dec 23;25(2):67. doi: 10.3892/ol.2022.13653. eCollection 2023 Feb.
There are currently no well-established treatment strategies for early esophageal squamous cell carcinoma (ESCC) for patients with only positive lateral margin (LM+) following endoscopic resection (ER). The present study aimed to find a treatment strategy for patients with early ESCC with non-curative resection (non-CR) and only LM+ following ER. In total, 511 patients with early ESCC treated at the Fourth Hospital of Hebei Medical University (Shijiazhuang, China) with ER were retrospectively analyzed, 41 of which (8%) were patients with only LM+ after non-CR. Of these, 28 patients received re-ER and 13 received additional surgical treatment. The clinicopathological characteristics of patients were analyzed and those who underwent additional surgery vs. re-ER were compared. Residual cancer cells were found in 27 patients (27/41, 65.9%) following re-ER or additional surgery. A significant increase in residual cancer cells was observed in patients with poorly differentiated cancer and patients with multiple LM+ (P=0.03 and P=0.015, respectively). Older patients and patients with single LM+ tended to choose re-ER (P=0.023 and P=0.038, respectively). In addition, there were three cases (3/13, 23.1%) of lymph node metastasis in the additional surgery group. However, within the limited follow-up time (mean, 36.1±24.1 months), no recurrence or metastasis was found in the remaining patients. The results showed that re-ER may be a more suitable additional therapy compared with surgery for patients with LM+ following non-CR, at least in the medium-term.
目前,对于内镜切除(ER)后仅侧缘阳性(LM+)的早期食管鳞状细胞癌(ESCC)患者,尚无成熟的治疗策略。本研究旨在为ER后非根治性切除(non-CR)且仅LM+的早期ESCC患者寻找一种治疗策略。对在河北医科大学第四医院(中国石家庄)接受ER治疗的511例早期ESCC患者进行回顾性分析,其中41例(8%)为non-CR后仅LM+的患者。其中,28例患者接受了再次ER,13例接受了额外的手术治疗。分析了患者的临床病理特征,并比较了接受额外手术与再次ER的患者。再次ER或额外手术后,27例患者(27/41,65.9%)发现残留癌细胞。在低分化癌患者和多个LM+患者中,残留癌细胞显著增加(分别为P=0.03和P=0.015)。老年患者和单个LM+患者倾向于选择再次ER(分别为P=0.023和P=0.038)。此外,额外手术组有3例(3/13,23.1%)发生淋巴结转移。然而,在有限的随访时间内(平均36.1±24.1个月),其余患者未发现复发或转移。结果表明,对于non-CR后LM+的患者,至少在中期,再次ER可能是比手术更合适的额外治疗方法。